TC
ARQT icon

Truvestments Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Truvestments Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.6K Buy
3,152
+140
+5% +$3.26K 0.01% 440
2026
Q1 		$71K Hold
3,012
– – 0.01% 449
2025
Q4 		$87.5K Buy
3,012
+1,606
+114% +$41.1K 0.02% 360
2025
Q3 		$26.5K Buy
1,406
+252
+22% +$3.97K ﹤0.01% 543
2025
Q2 		$16.2K Buy
+1,154
New +$16.2K ﹤0.01% 575

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Truvestments Capital's ARQT Position: Q2 2026 in Review

Truvestments Capital increased its Arcutis Biotherapeutics (ARQT) stake by 4.6% in Q2 2026, buying an estimated $3.26K and bringing the position to 3,152 shares worth $82.6K. The position accounts for 0.01% of the portfolio, ranked #440.

Truvestments Capital first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $87.5K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Truvestments Capital held 3,152 shares of Arcutis Biotherapeutics worth $82.6K as of Q2 2026.
  • Truvestments Capital bought 140 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.26K.
  • Arcutis Biotherapeutics made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #440 holding.
  • Truvestments Capital first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's Arcutis Biotherapeutics position peaked at $87.5K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.